Opendata, web and dolomites

MAMSCAN

New Method for Early Stage Breast Cancer Detection

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MAMSCAN project word cloud

Explore the words cloud of the MAMSCAN project. It provides you a very rough idea of what is the project "MAMSCAN" about.

2020    finalise    population    screenings    care    fall    amiqo    million    affordable    proprietary    ipr    economic    radiating    map    women    business    acceptance    ultrasound    ing    doctor    certification    services    company    76    significantly    consists    age    annually    sweden    foreseen    detection    considerable    outside    acquire    examination    fueled    oy    price    diagnosis    market    france    82    markets    solutions    accuracy    imaging    customers    scanning    clients    mammography    2026    share    societal    attain    gynecological    expensive    strategy    suspect    health    first    specialist    private    pipeline    healthcare    clinical    extensive    acquisition    30    neutral    direct    speed    alternative    planning    day    half    finland    pressure    device    clinics    images    groups    lower    2016    initial    sales    invasive    pointing    uk    mu    deadliest    stage    preventive    enhanced    competitors    found    cancer    anatomic    commercialization    solution    smei    decreased    treatment    effect    worked    imaqen    mortality    patented    launch    finnish    wavelength    frequency    breast    ai    diagnostic    spain    involve    50   

Project "MAMSCAN" data sheet

The following table provides information about the project.

Coordinator
IMAQEN OY 

Organization address
address: LIIKEHUONEISTO C JA D POHJOISRANTA 6 A
city: HELSINKI
postcode: 170
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Project website http://www.imaqen.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2019-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IMAQEN OY FI (HELSINKI) coordinator 50˙000.00

Map

 Project objective

Imaqen Oy is a Finnish healthcare technology company developing an imaging solution for the early detection of breast cancer. Since 2016, we have worked on our proprietary technology, Amiqo that has the same diagnostic accuracy as the key competitors, mammography and breast ultrasound, while it is non-invasive and non-radiating. Amiqo consists of an imaging device using a patented μm-wavelength scanning, a proprietary frequency analysis enhanced by AI and an anatomic map pointing out the suspect areas for diagnosis carried out by a specialist doctor. Our initial target customers are private health care clinics who already have gynecological services. They are under pressure of finding affordable solutions for preventive healthcare fueled by women’s increasing awareness of the importance of early detection. The economic effect is considerable: the operating costs are significantly lower, it enables more images taken/day and its acquisition cost is neutral or lower. The end-clients are women under 50 or over 70 who fall outside the population level mammography screenings. 50% of breast cancer cases are found in these age groups annually. For women, Amiqo examination will be less than half the price of any current alternative. Through lower mortality and decreased treatment costs, Amiqo has a direct impact at societal level as breast cancer is the most common, the deadliest and the most expensive cancer for women in Europe. The next steps involve extensive clinical testing to finalise the product design, acquire certification and attain clinical acceptance. The SMEI funding will speed up the business planning in our priority markets, Finland, Sweden, France, the UK and Spain, including IPR pipeline, clinical acceptance strategy, user and technical requirements. The commercialization stage will be achieved by €1,76 million with the launch foreseen in 2020. The first goal is a 30% market share of the non-invasive imaging market by 2026 resulting in sales of €82 million.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAMSCAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAMSCAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

RDNA (2019)

Empowering New Venture Growth - RDNA

Read More  

Manuback (2019)

MANUBACK, the smart garment for operator protection in the field of Manual Handling of Goods

Read More  

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More